Desescalation in Aromatase Inhibitors prescription for menopausal women with positive hormonal receptors breast cancers

Main Article Content



The use of aromatase inhibitors (AI) is widely accepted in positive hormonal receptors breast cancers. However a significant proportion of patient complain for side effects leading to abandon the treatment. Since the effect of AI is mainly based on the decrease of serum estradiol, the question of dose adaptation in decreasing the dosage of IA while keeping its biological effect was raised.


Recent papers brought major contribution in this field and we present here an analysis of some of these recent data validating the reduction of AI prescription without harm for the patient.

Keywords: breast cancers, Editorial

Article Details

How to Cite
SALMON, R. J.. Desescalation in Aromatase Inhibitors prescription for menopausal women with positive hormonal receptors breast cancers. Medical Research Archives, [S.l.], v. 12, n. 1, jan. 2024. ISSN 2375-1924. Available at: <>. Date accessed: 23 july 2024. doi:


[1] Hershman DL, Shao T, Kushi LH, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011;126(2):529-537

[2] Intermittent dosing of aromatase inhibitor to improve tolerance in post-menopausal women: a rationale for future clinical studies Cancer chemotherapy pharmacology 2015 75,(3), 653-55 Salmon R.J., Rey J.B., Launay Vacher V.

[3] Pfister C.U. et al Effect of age and single versus multiple dose pharamcokinetics of Letrozole in breast cancer patients Biopharm Drug Dispos 2001 22 191-197

[4] Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor – Positive Breast CancerA Randomized Clinical Trial Serrano et al. JAMA oncology 2023 mar23.e230089

[5] Effect of baseline oestradiol serum concentration on the efficacy of anastrozole for preventing breast cancer in postmenopausal women at high risk: a case-control study of the IBIS-II prevention trial Cuzick J. , Chu K. , Keevil B. , Brentnall A.R., Howell A. , Nicholas Zdenkowski N. , B., Loibl S.l, Holli K., Evans G. , CummingsS., Dowsett M. Lancet Oncology 2023 Dec 5:S1470-2045(23)00578-8. doi: 10.1016/S1470-2045(23)00578-8.
Online ahead of print.